Lv1
70 积分 2025-06-04 加入
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study
3个月前
已完结
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
3个月前
已完结
Therapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities
9个月前
已完结
皖公网安备34019202002308
